Search

Your search keyword '"Vahí, Maria"' showing total 8 results
Start Over Author "Vahí, Maria"
8 results on '"Vahí, Maria"'

1. Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice

Author

Celgene, Bristol Myers Squibb Foundation, Ramos, Fernando, Hermosín, Lourdes, Fuertes-Núñez, Marta, Martínez, Pilar, Rodríguez-Medina, Carlos, Barrios, Manuel, Ibáñez, Francisco, Bernal, Teresa, Olave, María-Teresa, Álvarez, Miguel Ángel, Vahí, Maria, Caballero-Velázquez, Teresa, González, Bernardo, Altés, Albert, García, Lorena, Fernández, Pascual, Durán, María Antonia, López, Rocío, Rafel, Montserrat, Serrano, Josefina, Celgene, Bristol Myers Squibb Foundation, Ramos, Fernando, Hermosín, Lourdes, Fuertes-Núñez, Marta, Martínez, Pilar, Rodríguez-Medina, Carlos, Barrios, Manuel, Ibáñez, Francisco, Bernal, Teresa, Olave, María-Teresa, Álvarez, Miguel Ángel, Vahí, Maria, Caballero-Velázquez, Teresa, González, Bernardo, Altés, Albert, García, Lorena, Fernández, Pascual, Durán, María Antonia, López, Rocío, Rafel, Montserrat, and Serrano, Josefina

Abstract

Acute myeloid leukemia has a poor prognosis in older adults, and its management is often unclear due to its underrepresentation in clinical trials. Both overall survival (OS) and health-related quality-of-life (HRQoL) are key outcomes in this population, and patient-reported outcomes may contribute to patient stratification and treatment assignment. This prospective study included 138 consecutive patients treated in daily practice with the currently available non-targeted therapies (intensive chemotherapy [IC], attenuated chemotherapy [AC], hypomethylating agents [HMA], or palliative care [PC]). We evaluated patients’ condition at diagnosis (Life expectancy [Lee Index for Older Adults], Geriatric Assessment in Hematology [GAH scale], HRQoL [EQ-5D-5L questionnaire], and fatigue [fatigue items of the QLQ-C30 scale]), OS, early death (ED), treatment tolerability (TT) and change in HRQoL over 12 months follow-up. The median OS was 7.1 months (IC not reached, AC 5.9, HMA 8.8, and PC 1.0). Poor risk AML category and receiving just palliative care, as well as a higher Lee index score in the patients receiving active therapy, independently predicted a shorter OS. The Lee Index and GAH scale were not useful for predicting TT. The white blood cell count was a valid predictor for ED. Patients’ HRQoL remained stable during follow-up.

Published
2023

2. Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia

Author

Sanchez-Garcia, Joaquin, Falantes-González, José Francisco, Medina Perez, Angeles, Hernandez-Mohedo, Francisca, Hermosín, Lourdes, Torres-Sabariego, Angeles, Bailen, Alicia, Hernandez-Sánchez, Jesus M., Solé Rodriguez, María, Casaño, Francisco Javier, Calderón-Cabrera, Cristina, Labrador, Maria, Vahí, Maria, Serrano-López, Josefina, Lumbreras, Eva, Hernández, Jesús M., Sanchez-Garcia, Joaquin, Falantes-González, José Francisco, Medina Perez, Angeles, Hernandez-Mohedo, Francisca, Hermosín, Lourdes, Torres-Sabariego, Angeles, Bailen, Alicia, Hernandez-Sánchez, Jesus M., Solé Rodriguez, María, Casaño, Francisco Javier, Calderón-Cabrera, Cristina, Labrador, Maria, Vahí, Maria, Serrano-López, Josefina, Lumbreras, Eva, and Hernández, Jesús M.

Abstract

In this prospective trial, the efficacy of azacitidine in lower-risk myelodysplastic syndromes (LR-SMD) lacking del(5q) was compared to best supportive care (BSC) at 1:1. The primary endpoint was the achievement of erythroid hematologic improvement (HI-E) after nine cycles. Thirty-six patients received at least ≥1 cycle. HI-E was confirmed 44.4% randomized to Aza and in 5.5% of patients receiving BSC (p <.01). After entry in Aza extension period, transfusion independence was achieved in all Aza responders with a median duration of 50 weeks (range: 17–231). No significant differences were observed in secondary endpoints. Importantly, variant allele frequency (VAF) of some mutated genes (RET, SF3B1, ASXL1) decreased after 9 months of treatment in Aza-responder patients. In conclusion, LR-MDS patients lacking del5q and resistant to ESAs, who receive 5 days Aza, achieve TI in a substantial proportion of cases and results in modifications in mutational landscape.

Published
2018

3. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience

Author

Labrador, Jorge, Saiz-Rodríguez, Miriam, De Miguel, Maria Dunia, Belén Vidriales, María, Perez Encinas, Manuel, Sanchez, Maria Jose, Cuello, Rebeca, Roldán Pérez, Alicia, Vives, Susana, Benzo Callejo, Gonzalo, Araujo, Mercedes Colorado, García-Fortes, María, Sayas, Maria Jose, Olivier, Carmen, Recio, Isabel, Conde Royo, Diego, Bienert Garcia, Alvaro, Vahi, Maria, Muñoz García, Carmen, Seri, Cristina, Tormo, Mar, Vall-llovera, Ferran, Foncillas, Maria Angeles, Martínez-Cuadron, David, Sanz, Miguel A., and Montesinos, Pau

Published
2020
Full Text
View/download PDF

4. Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.

Author

On behalf of Grupo Andaluz SMD, Sanchez-Garcia, Joaquin, Casaño, Francisco Javier, Serrano, Josefina, Falantes, Jose, Solé Rodriguez, María, Calderon, Cristina, Medina Perez, Angeles, Hernandez-Mohedo, Francisca, Hermosin, Lourdes, Torres-Sabariego, Angeles, Labrador, Maria, Vahí, Maria, Bailen, Alicia, Hernandez-Sanchez, Jesus M., Lumbreras, Eva, and Hernández-Rivas, Jesus Maria

Subjects
AZACITIDINE, MYELODYSPLASTIC syndromes, ANEMIA, GENETIC mutation, QUALITY of life
Abstract

In this prospective trial, the efficacy of azacitidine in lower-risk myelodysplastic syndromes (LR-SMD) lacking del(5q) was compared to best supportive care (BSC) at 1:1. The primary endpoint was the achievement of erythroid hematologic improvement (HI-E) after nine cycles. Thirty-six patients received at least ≥1 cycle. HI-E was confirmed 44.4% randomized to Aza and in 5.5% of patients receiving BSC (p < .01). After entry in Aza extension period, transfusion independence was achieved in all Aza responders with a median duration of 50 weeks (range: 17-231). No significant differences were observed in secondary endpoints. Importantly, variant allele frequency (VAF) of some mutated genes (RET, SF3B1, ASXL1) decreased after 9 months of treatment in Aza-responder patients. In conclusion, LR-MDS patients lacking del5q and resistant to ESAs, who receive 5 days Aza, achieve TI in a substantial proportion of cases and results in modifications in mutational landscape. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

5. Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory

Author

Gaya, Anna, Fuertes, Luis Fernando Fernández, Ballesteros Andrés, Mónica, De La Iglesia Íñigo, Silvia, Del Orbe Barreto, Rafael Andrés, Fernández Fuertes, Fernando, Gonzalez, Ana Pilar, Jarque, Isidro, Lavilla, Esperanza, Nuñez Vasquez, Ramiro, Salido, Eduardo José, Vahí, Maria, and Vallejo, Carlos

Abstract

Introduction: The introduction of C5 inhibitors (C5i) for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) has resulted in lower morbidity and mortality rates. However up to 86% of patients still experience anemia and fatigue in 63% of them which may impact their quality of life (QoL). The SATURNO study aimed to assess PNH patient and physician satisfaction with C5i treatment, along with the impact of the disease and clinical outcomes.

Published
2023
Full Text
View/download PDF

6. A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

Author

Díez Campelo, María, Davila, Julio, Mercedes, Sanchez Barba, Lopez-Pavia, Maria, Such, Esperanza, Bernal, Teresa, Luño, Elisa, Ramos, Fernando, Calabuig, Marisa, Pomares, Helena, Gonzalez, Bernardo, Merchan, Brayan, Barranco, Edgardo, Sancho Tello, Reyes, Callejas, Marta, Requena, Maria Jose, Jiménez, María José, Pedreño, Maria, Medina, Angeles, Vicente, Ana I, Campeny, Andrea, Cortes Sansa, Montse, Pedro, Carmen, Falantes, Jose, Arilla, Maria Jesus, Bárez, Abelardo, Garcia, Regina, Arcos, Maria Jose, Gomez, Valle, Muñoz, Carolina, Cervero, Carlos, Casaño, Javier, De Paz, Raquel, Amigo, Luz, Insunza, Andres, Muñoz, Juan Antonio, Cedena, Maria Teresa, Gomez, Marta, Font, Patricia, Del Campo, Raquel, Fernandez Lago, Carlos, Gonzalez Hurtado, Jose Antonio, Linares Latorre, Maria Dolores, Mora Casado, Asuncion, Vahi, Maria, Benlloch, Luis, Sanz, Guillermo, and Cañizo, María Consuelo

Published
2015
Full Text
View/download PDF

7. Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study

Author

Pardal, Emilia, Diez-Baeza, Eva, González-Barca, Eva, Garcia-Cerecedo, Tomas, Monzo, Encarna, Sancho, Juan-Manuel, Moraleda, Jose Maria, Cordoba, Raul, De la Cruz, Fatima, Queizan, JA, Rodriguez-Salazar, Maria, Hernández-Rivas, JA, Navarro, Belen, Diez-Angulo, Rosana, Viguria, Maria Cruz, Vahi, Maria, Peñarrubia, Maria Jesús, Sanchez, Monica, Canales, Miguel, Gonzalez, Tomas, Alonso, Sara, Caballero, Maria Dolores, and Martin, Alejandro

Published
2015
Full Text
View/download PDF

8. Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.

Author

Sanchez-Garcia J, Falantes J, Medina Perez A, Hernandez-Mohedo F, Hermosin L, Torres-Sabariego A, Bailen A, Hernandez-Sanchez JM, Solé Rodriguez M, Casaño FJ, Calderon C, Labrador M, Vahí M, Serrano J, Lumbreras E, and Hernández-Rivas JM

Subjects
Aged, Aged, 80 and over, Anemia epidemiology, Antimetabolites, Antineoplastic therapeutic use, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes pathology, Prognosis, Prospective Studies, Survival Rate, Anemia therapy, Azacitidine therapeutic use, Blood Transfusion methods, Chromosome Deletion, Chromosomes, Human, Pair 5 genetics, Myelodysplastic Syndromes therapy, Palliative Care
Abstract

In this prospective trial, the efficacy of azacitidine in lower-risk myelodysplastic syndromes (LR-SMD) lacking del(5q) was compared to best supportive care (BSC) at 1:1. The primary endpoint was the achievement of erythroid hematologic improvement (HI-E) after nine cycles. Thirty-six patients received at least ≥1 cycle. HI-E was confirmed 44.4% randomized to Aza and in 5.5% of patients receiving BSC (p < .01). After entry in Aza extension period, transfusion independence was achieved in all Aza responders with a median duration of 50 weeks (range: 17-231). No significant differences were observed in secondary endpoints. Importantly, variant allele frequency (VAF) of some mutated genes (RET, SF3B1, ASXL1) decreased after 9 months of treatment in Aza-responder patients. In conclusion, LR-MDS patients lacking del5q and resistant to ESAs, who receive 5 days Aza, achieve TI in a substantial proportion of cases and results in modifications in mutational landscape.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results